{"In": [0], "a": [1, 63, 73, 94, 133, 164, 230], "previous": [2], "analysis": [3, 59, 119], "of": [4, 55, 60, 93, 103, 120, 130, 136], "this": [5], "phase": [6], "3": [7], "trial,": [8], "first-line": [9], "ribociclib": [10, 47, 79, 149, 189, 226, 259], "plus": [11, 161, 173, 190, 202, 227, 239], "letrozole": [12, 20, 162, 191, 203, 228, 240], "resulted": [13], "in": [14, 72, 82, 147, 156, 241], "significantly": [15], "longer": [16, 45, 257], "progression-free": [17, 121], "survival": [18, 41, 87, 122, 125, 167, 177, 233, 251], "than": [19, 254, 260], "alone": [21], "among": [22, 143, 153], "postmenopausal": [23], "patients": [24, 145, 242], "with": [25, 46, 84, 90, 100, 171, 188, 200, 225, 237, 243, 258, 261], "hormone": [26], "receptor": [27, 33], "(HR)-positive,": [28], "human": [29], "epidermal": [30], "growth": [31], "factor": [32], "2": [34], "(HER2)-negative": [35], "advanced": [36, 246], "breast": [37, 247], "cancer.": [38, 248], "Whether": [39], "overall": [40, 61, 124, 166, 176, 232, 250], "would": [42], "also": [43], "be": [44], "was": [48, 88, 115, 178, 252], "not": [49], "known.Here": [50], "we": [51], "report": [52], "the": [53, 56, 91, 101, 118, 128, 131, 148, 157], "results": [54], "protocol-specified": [57], "final": [58], "survival,": [62], "key": [64], "secondary": [65], "end": [66], "point.": [67], "Patients": [68], "were": [69, 222], "randomly": [70], "assigned": [71], "1:1": [74], "ratio": [75, 205], "to": [76, 126, 186, 198, 212], "receive": [77], "either": [78], "or": [80], "placebo": [81, 158, 172, 201, 238], "combination": [83], "letrozole.": [85, 174], "Overall": [86], "assessed": [89], "use": [92, 102], "stratified": [95], "log-rank": [96], "test": [97], "and": [98, 123, 151, 192], "summarized": [99], "Kaplan-Meier": [104], "methods": [105], "after": [106], "400": [107], "deaths": [108, 140], "had": [109, 141], "occurred.": [110], "A": [111], "hierarchical": [112], "testing": [113], "strategy": [114], "used": [116], "for": [117, 206], "ensure": [127], "validity": [129], "findings.After": [132], "median": [134], "follow-up": [135], "6.6": [137], "years,": [138], "181": [139], "occurred": [142], "334": [144, 154], "(54.2%)": [146], "group": [150], "219": [152], "(65.6%)": [155], "group.": [159], "Ribociclib": [160], "showed": [163, 229], "significant": [165, 231], "benefit": [168, 234], "as": [169, 235], "compared": [170, 236], "Median": [175, 249], "63.9": [179], "months": [180, 194, 256], "(95%": [181, 195], "confidence": [182], "interval": [183], "[CI],": [184], "52.4": [185], "71.0)": [187], "51.4": [193], "CI,": [196, 210], "47.2": [197], "59.7)": [199], "(hazard": [204], "death,": [207], "0.76;": [208], "95%": [209], "0.63": [211], "0.93;": [213], "two-sided": [214], "P": [215], "=": [216], "0.008).": [217], "No": [218], "new": [219], "safety": [220], "signals": [221], "observed.First-line": [223], "therapy": [224], "HR-positive,": [244], "HER2-negative": [245], "more": [253], "12": [255], "placebo.": [262], "(Funded": [263], "by": [264], "Novartis;": [265], "MONALEESA-2": [266], "ClinicalTrials.gov": [267], "number,": [268], "NCT01958021.).": [269]}